Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis

Trial Profile

Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Golimumab (Primary) ; Infliximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms AWARE
  • Sponsors Janssen
  • Most Recent Events

    • 27 Dec 2017 Planned number of patients changed from 1200 to 1320.
    • 08 Nov 2017 Interim results assessing patient response to Patient Reported Outcomes Measurement Information System (PROMIS) questionnaires, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 08 Nov 2017 Interim analysis (n=747) results assessing the golimumab and Infliximab utilization patterns, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top